Journal of gastroenterology and hepatology

Travel medicine and infectious disease

[1] Aspartate aminotransferase to platelet ratio index as a prospective predictor of hepatocellular carcinoma risk in patients with chronic hepatitis B virus infection.

[2] combined ultrasound and nerve stimulator-guided deep nerve block may decrease the rate of local anesthetics systemic toxicity: a randomized clinical trial

[3] epidemiology and molecular characterization of hepatitis b virus in luanda, angola

[4] identifying and characterizing interplay between hepatitis b virus x protein and smc5/6

[5] impact of maternal hbsag carrier status on pregnancy outcomes in duhok city, iraq

[6] اثر ایندومتاسین در کاهش حجم مایع آمنیوتیک در پلی هیدرآمنیوس متوسط و شدید

[7] proposed electronic medical record with emphasis on hepatitis diagnosis

[8] antiviral therapy against chronic hepatitis b in brazil: high rates of lamivudine resistance mutations and correlation with hbv genotypes

[9] possible impact of 190g > a ccr2 and Δ32 ccr5 mutations on decrease of the hbv vaccine immunogenicity—a preliminary report

[10] perinatal transmission of hepatitis viruses: the possible mechanisms

[11] dna tumor virus regulation of host dna methylation and its implications for immune evasion and oncogenesis

[12] Characteristics of HBV infection in 705 HIV-infected patients under lamivudine-based antiretroviral treatment from three regions in China

[13] Naturally occurring genotypic drug-resistant mutations of HBV in Huzhou, China: a single-center study

[14] Genotyping of HBV and tracking of resistance mutations in treatment-naïve patients with chronic hepatitis B

[15] Characteristics of HBV infection in 705 HIV-infected patients under lamivudine-based antiretroviral treatment from three regions in China

[16] Naturally occurring genotypic drug-resistant mutations of HBV in Huzhou, China: a single-center study

[17] Genotyping of HBV and tracking of resistance mutations in treatment-naïve patients with chronic hepatitis B

[18] Evaluation of the HBV Genotype, Viral Load and Antivirus Drug Resistance Mutation in Tay Ninh Hospital, Vietnam by Real-Time PCR

[19] Influence of maintained hemodialysis on viral load in patients with end-stage renal disease with HBV infection

[20] Incorporation of Carbon Nanofillers Tunes Mechanical and Electrical Percolation in PHBV:PLA Blends

[21] Mapping the Interactions of HBV cccDNA with Host Factors.

[22] Hepatitis B virus (HBV) infection and liver disease after allogeneic bone marrow transplantation: a report of 30 cases.

[23] Diatom shell incorporated PHBV/PCL-pullulan co-electrospun scaffold for bone tissue engineering.

[24] Anti-HBV and anti-HIV activities of dioxolane-purine nucleosides

[25] 94 Anti-HBV and HIV activities of Chinese herb Qing Yang Can (QYC)

[26] The Positive Fate of Biochar Addition to Soil in the Degradation of PHBV-Silver Nanoparticle Composites.

[27] Polymer blend of PLA/PHBV based bionanocomposites reinforced with nanocrystalline cellulose for potential application as packaging material.

[28] Design, synthesis and anti-HBV activity evaluation of new substituted imidazo[4,5-b]pyridines.

[29] What is changed in HBV molecular epidemiology in Italy?

[30] Case reports of latent HBV hepatitis in patients after neurosurgical treatment for hypothalamic and pituitary tumors

[31] Head and neck squamous cell carcinoma in HIV, HBV and HCV seropositive patients - Prognosis and its predictors

[32] Head and neck squamous cell carcinoma in HIV, HBV and HCV seropositive patients - Prognosis and its predictors

[33] chronic active hepatitis b with hbv-associated nephropathy: close resemblance to lupus nephritis

[34] relationship between hbv dna and hbeag in serum and hbcag and inflammation grade in liver tissue among patients with chronic hepatitis b

[35] the silence of muc2 mrna induced by promoter hypermethylation associated with hbv in hepatocellular carcinoma

[36] serum/plasma micrornas as biomarkers for hbv-related hepatocellular carcinoma in china

[37] efficacy of antiviral therapy in hepatocellular carcinoma patients with high hbv-dna levels after radical resection

[38] parv4 prevalence, phylogeny, immunology and coinfection with hiv, hbv and hcv in a multicentre african cohort [version 1; referees: 2 approved]

[39] are hiv, hbv and hcv voluntary counseling and testing programs needed in balkans?

[40] analysis of a new delayed hbv model with exposed state and immune response to infected cells and viruses

[41] hbv genotype distribution and its relationship with serum hbv dna level and hbeag expression among patients with chronic hepatitis b in southern zhejiang province, china

[42] high level of hbv dna virus in the breast milk seems not to contraindicate breastfeeding

[43] in vitro degradation of phbv scaffolds and nha/phbv composite scaffolds containing hydroxyapatite nanoparticles for bone tissue engineering

[44] hgv-hcv/hbv co-infection in india: a pilot study

[45] efficacy and safety of telbivudine in preventing mother-to-infant transmission of hbv in pregnant women with high hbv dna load

[46] 153例慢性hbv感染者核苷和核苷酸类药物的耐药变异位点分析

[47] immunity and fibrogenesis: the role of th17/il-17 axis in hbv and hcv-induced chronic hepatitis and progression to cirrhosis

[48] significance and progress in detection of hbv cccdna in peripheral blood mononuclear cells

[49] the comparative efficacy and safety of entecavir and lamivudine in patients with hbv-associated acute-on-chronic liver failure: a systematic review and meta-analysis

[50] blood serum alpha fetoprotein enhancer binding protein, a tumor suppressor, decreases in chronic hbv hepatitis patients as hepatocellular cancer appears

[51] identification of new sources of resistance to rhbv- rice hoja blanca virus

[52] naturally occurring genotypic drug-resistant mutations of hbv in huzhou, china: a single-center study

[53] antiviral therapy against chronic hepatitis b in brazil: high rates of lamivudine resistance mutations and correlation with hbv genotypes

[54] liver fibrosis in treatment-naïve hiv-infected and hiv/hbv co-infected patients: zambia and switzerland compared

[55] possible impact of 190g > a ccr2 and Δ32 ccr5 mutations on decrease of the hbv vaccine immunogenicity—a preliminary report

[56] value of model for end-stage liver disease score combined with neutrophil-lymphocyte ratio in predicting the short-term prognosis of patients with hbv-related acute-on-chronic liver failure

[57] relationship between hbv dna level and pathological changes of liver tissue in hbeag-negative patients with chronic hbv infection

[58] stability analysis of a fractional-order hbv infection model

[59] A severe hepatitis flare in an HBV-HCV coinfected patient during combination therapy with alpha-interferon and ribavirin